These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29171488)

  • 1. [The efficacy of recognan in the early stage of ischemic stroke].
    Mashin VV; Belova LA; Dudikov EM; Bergelson TM; Lankov VA; Zakuraeva KA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):44-48. PubMed ID: 29171488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology].
    Mashin VV; Belova LA; Bakhtogarimov IR; Bergelson TM; Sharafutdinova RR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):39-43. PubMed ID: 28884715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of the use of the drug recognan (citicoline) on the state of higher mental functions in patients with mild cognitive impairment].
    Nemkova SA; Semenov DV; Petrova EA; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(9):51-57. PubMed ID: 34693689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The assessment of the efficacy of citicoline in the early and recovery stages of stroke].
    Shavlovskaya OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):93-97. PubMed ID: 28635796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence of the drug recognan (citicoline) on neurodynamic characteristics of mental activity in patients with mild cognitive impairment].
    Nemkova SA; Semenov DV; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(1):43-46. PubMed ID: 33580760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms].
    Shavlovskaya OA; Bokova IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11):22-28. PubMed ID: 37994884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology].
    Belova LA; Mashin VV; Dudikov EM; Belov DV; Krupennikov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2):35-38. PubMed ID: 30874524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Citicoline in vascular cognitive impairment and vascular dementia after stroke.
    Alvarez-Sabín J; Román GC
    Stroke; 2011 Jan; 42(1 Suppl):S40-3. PubMed ID: 21164117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment.
    Alvarez-Sabín J; Ortega G; Jacas C; Santamarina E; Maisterra O; Ribo M; Molina C; Quintana M; Román GC
    Cerebrovasc Dis; 2013; 35(2):146-54. PubMed ID: 23406981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of neuroprotection in complex rehabilitation of patients with ischemic stroke].
    Hubenia OV
    Lik Sprava; 2012; (7):88-92. PubMed ID: 23350122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline)].
    Nemkova SA; Semenov DV; Petrova EA; Savchenko DV; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(7):27-34. PubMed ID: 31464286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Possibilities of cavinton therapy regimen for infusions and cavinton comforte in acute and early recovery periods after ischemic stroke].
    Belova LA; Mashin VV; Proshin AN; Ovsyannicova AN; Kostishko BB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):51-58. PubMed ID: 29053121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of citicoline as an acute stroke treatment.
    Clark WM
    Expert Opin Pharmacother; 2009 Apr; 10(5):839-46. PubMed ID: 19351232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citicoline: pharmacological and clinical review, 2006 update.
    Secades JJ; Lorenzo JL
    Methods Find Exp Clin Pharmacol; 2006 Sep; 28 Suppl B():1-56. PubMed ID: 17171187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is aura around citicoline fading? A systemic review.
    Agarwal S; Patel BM
    Indian J Pharmacol; 2017; 49(1):4-9. PubMed ID: 28458415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citicoline in the treatment of acute ischaemic stroke: an international, randomized, multicentre, placebo-controlled study (ICTUS trial) is the use of Citicoline is beneficial for acute ischaemic stroke?
    Nomani F; Kamal AK
    J Pak Med Assoc; 2013 Nov; 63(11):1445. PubMed ID: 24392540
    [No Abstract]   [Full Text] [Related]  

  • 17. [Features of positive personality phenomena in patients with mild cognitive impairment and asthenic syndrome treated with recognan (citicoline)].
    Nemkova SA; Semenov DV; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(1):44-50. PubMed ID: 32105268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probably role of citicoline in stroke rehabilitation: review of the literature.
    Secades JJ
    Rev Neurol; 2012 Feb; 54(3):173-9. PubMed ID: 22278894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citicoline preclinical and clinical update 2009-2010.
    Dávalos A; Secades J
    Stroke; 2011 Jan; 42(1 Suppl):S36-9. PubMed ID: 21164116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases.
    Cho HJ; Kim YJ
    Methods Find Exp Clin Pharmacol; 2009 Apr; 31(3):171-6. PubMed ID: 19536360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.